Evaluación positiva de medicamentos: marzo/abril/mayo 2015 Sanid. mil. 2015; 71 (3) 195 32. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bonderenko I et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetoge-nic chemotherapy. Ann Oncol. 2014 Jul;25(7):1328-33. Disponible en: http:// annonc.oxfordjournals.org/content/25/7/1328.long 33. Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemoterapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014 Jul;25(7):1333- 9. Disponible en: http://annonc.oxfordjournals.org/content/25/7/1333.long 34. Natale JJ, Spinelli T, Calcagnile S, Lanzarotti C, Rossi G, Cox D et al. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.J Oncol Pharm Pract. 2015 May 20. Disponible en: http://opp.sagepub.com/content/ear ly/2015/06/11/1078155215586824.long 35. Committe for Medical Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_ opinion_-_Initial_authorisation/human/003985/WC500186144.pdf 36. Espinosa E. Congreso nacional de oncología médica. Salamanca 2013. Mecanismo de acción de Nivolumab. Disponible en: http://www.seom.org/ seomcms/images/stories/recursos/ponencias/2013/viernes/2_2_Espinosa_me-lanoma_ SEOM_2013.pdf 37. Food and Drugs administration. Press announcements. FDA expands appro-ved use of Opdivo to treat lung cancer. Disponible en: http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm436534.htm 38. Weber JS, D’Angelo SP, Minor D, Hodi FS et al. Nivolumab versus che-motherapy in patients with advanced melanoma who progressed after anti- CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. Disponible en: http:// www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970076- 8/fulltext 39. Robert C, Long GV, Brady B, Dutriaux C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. Disponible en: http://www.nejm.org/doi/full/10.1056/NE-JMoa1412082 40. Postow MA, Chesney J, Pavlick AC, Robert C et al. Nivolumab and ipilimu-mab versus ipilimumad in untreated melanoma.N Engl J Med. 2015 May 21;372(21):2006-17. Disponible en: http://www.nejm.org/doi/full/10.1056/ NEJMoa1414428 41. Committe for Medical Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_ opinion_-_Initial_authorisation/human/003840/WC500187124.pdf 42. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small- Cell Lung Cancer. N Engl J Med. 2015 May 31. Disponible en: http://www. nejm.org/doi/full/10.1056/NEJMoa1504627 43. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20;33(18):2004-12. Disponible en: http://www.ncbi.nlm.nih.gov/pub-med/ 25897158 44. Committe for Medical Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_ opinion_-_Initial_authorisation/human/003820/WC500187081.pdf 45. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembro-lizumab versus Ipilimumab in Advanced Melanoma. N Eng J Med. 2015 Jun 25;372(26):2521-32. Disponible en: http://www.nejm.org/doi/full/10.1056/ NEJMoa1503093 46. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al. Anti-programmed- death-receptor-1 treatment with pembrolizumab in ipilimu-mab- refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25034862 47. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. Disponible en: http://www.ncbi.nlm.nih. gov/pubmed/25891174 48. Cardinali DP, Cano P, Jimenez-Ortega V, Esquifino, AI. Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications. Neu-roendocrinology 2011; 93: 133–142. 49. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insom-nia and circadian rhythm sleep disorders. Curr. Opin. Investig. Drugs 2009; 10: 691–701. 50. Mulchahey JJ, Goldwater DR, Zemlan, FP. A single blind, placebo con-trolled, across groups dose escalation study of the safety, tolerability, phar-macokinetics and pharmacodynamics of the melatonin analog β-methyl-6- chloromelatonin. Life Sci. 2004; 75: 1843–1856. 51. Laudon M, Frydman-Marom A. Therapeutic effects of melatonin recep-tor agonists on sleep and comorbid disorders. Int. J. Mol. Sci 2014; 15: 15924-50. 52. Committe for Medical Products for Human Use (CHMP). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_ opinion_-_Initial_authorisation/human/003852/WC500184904.pdf 53. GARDASIL®. FICHA TÉCNICA. Disponible en: http://www.ema.euro-pa. eu/docs/es_ES/document_library/EPAR_-_Product_Information/hu-man/ 000703/WC500021142.pdf 54. Koutsky L, for the FUTURE II Study Group. Quadrivalent vaccine aga-inst human papi-llomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/17494925 55. Ault KA, for the FUTURE II Study Group. Efficacy of a prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369(9576): 1861-8.50. Disponible en: http://www.ncbi.nlm.nih.gov/pub-med/ 17544766 56. Garland SM, Hernández-Ávila M, Wheeler CM, Pérez G, Harper DM, Leo-dolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19): 1928-43.51. Disponible en: http://content.nejm.org/cgi/content/full/356/19/1928 57. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young wo-men: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580): 2161-70.52. Disponible en: http://www.ncbi. nlm.nih.gov/pubmed/17602732 58. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK et al. An Overview of quadrivalent Human Papillomavirus Vaccine Safety-2006 to 2015. Pediatr Infect Dis J. 2015 Jun 22. Disponible en: http://www.ncbi.nlm. nih.gov/pubmed/26107345 59. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J et al. A 9-Valent HPV Vaccine against Infection and Intraepitethelial Neoplasia in Women.N ENG J MED.2015 Feb 19; 372: (8):711-23. Disponible en: http:// www.ncbi.nlm.nih.gov/pubmed/25693011
REVISTA DE SANIDAD FAS JUL SEP 2015
To see the actual publication please follow the link above